AstraZeneca Pharma India Limited (ASTRAZEN.NS)
- Previous Close
5,245.45 - Open
5,324.15 - Bid --
- Ask --
- Day's Range
5,245.00 - 5,324.15 - 52 Week Range
3,115.05 - 7,220.95 - Volume
2,127 - Avg. Volume
20,837 - Market Cap (intraday)
132.291B - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
95.05 - EPS (TTM)
55.60 - Earnings Date May 28, 2024 - Jun 1, 2024
- Forward Dividend & Yield 16.00 (0.31%)
- Ex-Dividend Date Jul 14, 2023
- 1y Target Est
--
AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brand names; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brand names. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
www.astrazeneca.in947
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: ASTRAZEN.NS
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASTRAZEN.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASTRAZEN.NS
Valuation Measures
Market Cap
131.31B
Enterprise Value
126.03B
Trailing P/E
94.17
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.96
Price/Book (mrq)
20.02
Enterprise Value/Revenue
10.53
Enterprise Value/EBITDA
61.41
Financial Highlights
Profitability and Income Statement
Profit Margin
11.64%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
11.97B
Net Income Avi to Common (ttm)
1.39B
Diluted EPS (ttm)
55.60
Balance Sheet and Cash Flow
Total Cash (mrq)
5.2B
Total Debt/Equity (mrq)
0.82%
Levered Free Cash Flow (ttm)
--
Company Insights: ASTRAZEN.NS
ASTRAZEN.NS does not have Company Insights